Novartis reported strong third-quarter earnings, exceeding analyst expectations and raising its full-year guidance. However, the company faced a setback with a delayed pelabresib filing, leading to an impairment charge. Despite this, Novartis remains optimistic about its future growth, particularly in the radiopharmaceutical market with its Pluvicto drug, while facing competition from other companies developing similar therapies.